Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population

详细信息    查看全文

• 作者：Savino Bruno¹ ; ^{savino.bruno@hunimed.eu" class="auth_mail" title="E-mail the corresponding author} ; Vito Di Marco² ; Massimo Iavarone³ ; Luigi Roffi⁴ ; Andrea Crosignani⁵ ; Vincenza Calvaruso² ; Alessio Aghemo³ ; Giuseppe Cabibbo² ; Mauro Viganò ; ³ ; Vincenzo Boccaccio¹ ; Antonio Craxí ; ² ; Massimo Colombo³ ; Patrick Maisonneuve⁶
• 关键词：SVR ; HCV-related cirrhosis ; IFN-based therapy ; DAA&rsquo ; s ; Antiviral therapy
• 刊名：Journal of Hepatology
• 出版年：2016
• 出版时间：June 2016
• 年：2016
• 卷：64
• 期：6
• 页码：1217-1223
• 全文大小：950 K

文摘

Life expectancy of patients with compensated hepatitis C virus (HCV) cirrhosis achieving sustained virologic response (SVR) is limited by liver events as compared to the general population. Thus, survival benefit of SVR remains to be measured.

Methods

The study includes prospective surveillance data from three cohorts of Italian patients with compensated HCV cirrhosis who achieved SVR on an interferon-based (IFN) regimen, compared to simultaneously observed non-SVR, untreated and decompensated patients. Overall survival was calculated from the date of start of IFN to death. The number of deaths expected during the at-risk period was determined by applying age- and sex-specific mortality rates recorded in Italy for person-years adequate for the enrolment period. The standardized mortality ratio (SMR) determined the relative risk of death over that of the age and sex matched general population.

Results

Overall, 28/181 patients followed-up for a median period of 9.6 years (range 1–25 years) died. The 10 and 20-year overall survival rates for the whole series were 90.9% (95% CI, 84.3–94.8) and 62.9% (95% CI, 45.9–75.9), respectively. The number of expected deaths in the corresponding age and sex matched general population was 28.1, corresponding to a SMR = 1.00 (95% CI, 0.72–1.35), with an SMR for non-SVR patients of 3.85 (95% CI, 3.43–4.30), for untreated of 3.01 (95% CI, 2.64–3.42) and for decompensated of 6.70 (95% CI, 5.39–8.22).

Conclusions

Patients with compensated HCV cirrhosis achieving SVR by IFN obtain a main benefit levelling their survival curve to that of the general population. Wider applicability of IFN-free regimens will possibly make this achievement more generalizable.